Business Wire

31. Cofactor Genomics Announces Strategic Investment By Labcorp And Ascension Ventures To Fuel Expansion Of Its OncoPrism Immunotherapy Diagnostic Across U.S. Cancer Care Networks 12/15/2025

    Cofactor Genomics, a commercial-stage diagnostics company transforming precision oncology through RNA-based predictive tests, today announced strategic investments from Labcorp and Ascension Ventures.

32. Overture Life And CEGYR Establish First Automated Embryology Center Of Excellence To Set Global Benchmark For Reproducible IVF Outcomes Across High-Volume Fertility Networks 12/15/2025

    Overture Life, the global leader in automated IVF and the first company to achieve live births from both robotic fertilization and robotic egg freezing, today announced the establishment of its first Center of Excellence for Automated Embryology in partnership with CEGYR, a flagship fertility program within the Eugin Group.

33. Idengene SA To Bring Contextual Genomics' Revolutionary Cancer Genomic Test Find-It To Brazil 11/9/2017

    Brazilian diagnostics company Idengene SA has partnered with leading Canadian cancer genomics company Contextual Genomics to bring Find-It™, a potentially revolutionary genomic test, to Brazil. Idengene will offer Find-It™ at its laboratory in Brazil to patients diagnosed with cancer

34. New Benchtop Centrifuge Incorporates Hybrid Rotor For Application Flexibility 2/4/2016

    Clinical and life science researchers can now benefit from a new benchtop centrifuge that features a unique 2-in-1 hybrid rotor that has interchangeable fixed-angle and swinging buckets to facilitate quick and convenient switching between applications

35. First Patient Enrolled In Dabigatran Study Comparing Anticoagulation Strategies During AF Ablation 5/13/2015

    The first patient with atrial fibrillation (AF) has been enrolled in the global RE-CIRCUIT™ study.⁴ The study assesses the safety and efficacy of uninterrupted anticoagulation with dabigatran etexilate (Pradaxa^®) during ablation procedures compared to warfarin.¹ Results from the RE-CIRCUIT™ study are expected during 2016

36. Thermo Fisher Scientific Releases New CE-IVD Tumor Panel For Next Generation Sequencing 1/13/2015

    The newly released CE-IVD Oncomine Solid Tumor DNA kit from Thermo Fisher Scientific enables highly accurate and reliable multiplexed sequencing of formalin-fixed, paraffin embedded (FFPE) tumor samples with the quality and performance needed for the clinical laboratory

37. One Lambda Announces The Availability Of Its New RUO NXType Kit, A Complete Solution For HLA Typing By NGS 12/1/2014

    One Lambda, Inc., part of Thermo Fisher Scientific and leading producer of research and in vitro diagnostic products for the HLA transplant community, recently launched its RUO NXType Kit, a research use only (RUO) solution for human leukocyte antigen (HLA) typing by next-generation sequencing (NGS)

38. AB SCIEX Launches Next-Generation TripleTOF 5600 System 5/21/2012

    AB SCIEX, a global leader in life science analytical technologies, recently announced the launch of the second generation of the TripleTOF 5600 System. 

39. Thermo Fisher Scientific Announces 510 Clearance Of ImmunoCAP Tryptase Assay 3/9/2012
    Thermo Fisher Scientific Inc., the world leader in serving science, recently announced that its immunodiagnostics business has received 510(k) clearance of the Thermo Scientific ImmunoCAP Tryptase Assay for use on its Thermo Scientific Phadia Laboratory Systems line of automated laboratory instruments
40. Almac Invests GBP 1M In Dedicated Mass Spectrometry Laboratory 10/21/2011
    Almac has established a dedicated mass spectrometry laboratory in their European Headquarters, Craigavon, UK